| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.1994.12.9.1886 |
| P698 | PubMed publication ID | 8083712 |
| P50 | author | J Gregory Cairncross | Q114727084 |
| P2093 | author name string | D H Lee | |
| D R Macdonald | |||
| C J Watling | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| P304 | page(s) | 1886-1889 | |
| P577 | publication date | 1994-09-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. | |
| P478 | volume | 12 |
| Q35570245 | "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. |
| Q36608763 | A mathematical modelling tool for predicting survival of individual patients following resection of glioblastoma: a proof of principle |
| Q55475071 | Accelerated radiotherapy with concomitant ACNU/Ara-C for the treatment of malignant glioma. |
| Q39030177 | Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma |
| Q38855020 | Assessment of Brain Tumor Response: RANO and Its Offspring |
| Q33606041 | Chemotherapy for adults with malignant glioma |
| Q33724545 | Chemotherapy for brain metastases of lung cancer: a review |
| Q41124100 | Chemotherapy of cerebral metastases from solid tumors. |
| Q38990624 | Clinical Relevance of Steroid Use in Neuro-Oncology |
| Q37839482 | Clinical trial end points for high-grade glioma: the evolving landscape. |
| Q33518926 | Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme |
| Q88775005 | Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group |
| Q40939911 | Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan |
| Q24797338 | Dexamethasone inhibits the HSV-tk/ ganciclovir bystander effect in malignant glioma cells |
| Q33447142 | End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria |
| Q36168293 | Glioblastoma presenting with steroid-induced pseudoregression of contrast enhancement on magnetic resonance imaging |
| Q36082476 | Growth dynamics of untreated glioblastomas in vivo |
| Q37115120 | Identification of early and distinct glioblastoma response patterns treated by boron neutron capture therapy not predicted by standard radiographic assessment using functional diffusion map. |
| Q51800219 | Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value. |
| Q30692995 | Invited review--neuroimaging response assessment criteria for brain tumors in veterinary patients |
| Q36869065 | Low grade gliomas: functional mapping resection strategies, extent of resection, and outcome |
| Q49051115 | MRI and thallium-201 SPECT in the prediction of survival in glioma |
| Q48452997 | MRI measurement of brain tumor response: comparison of visual metric and automatic segmentation |
| Q37152041 | Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study |
| Q33388541 | Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma |
| Q33380081 | Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas. |
| Q88561331 | Postcontrast T1 Mapping for Differential Diagnosis of Recurrence and Radionecrosis after Gamma Knife Radiosurgery for Brain Metastasis |
| Q47734339 | Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas |
| Q52893343 | Quantitative computer-assisted analysis vs. visual estimation of MR imaging response of brain metastases to radiotherapy. |
| Q34331320 | Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). |
| Q37810523 | Response Assessment in Neuro-Oncology |
| Q88852234 | Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma |
| Q37738776 | Response assessment challenges in clinical trials of gliomas |
| Q30607148 | Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. |
| Q96165810 | Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group |
| Q42246513 | Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase |
| Q37930388 | Standard of care therapy for malignant glioma and its effect on tumor and stromal cells |
| Q48836301 | The Charing Cross Hospital experience with temozolomide in patients with gliomas |
| Q36895970 | The effect of dexamethasone on the uptake of cisplatin in 9L glioma and the area of brain around tumor. |
| Q34399296 | What have we learnt from previous phase II trials to help in the management of childhood brain tumours? |
Search more.